Eisai's Regional Shift, Or Just Restructuring? Daiichi Sankyo's U.S. Ranbaxy Dip: Japanese Earnings Roundup (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's note: This is part two of a two-part feature on Japanese pharma earnings; part one covered Dainippon Sumitomo Pharma Co. Ltd. and its failed pan-Asia trials and Mitsubishi Tanabe Pharma Corp.'s efforts to rebound from Japan's March 11 earthquake. This second part covers Eisai Co. Ltd. and Daiichi Sankyo Co. Ltd.]